October 29 | 2021 2cureX – Banbrytande cancerbehandlingstest rullas ut – Mangold Insight Analys Read more
October 15 | 2021 2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant. Read more
October 12 | 2021 2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021. Read more
September 28 | 2021 Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain Read more
August 26 | 2021 2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2021 Read more
August 26 | 2021 2cureX publishes interim report for the second quarter and first half of 2021 Read more
June 1 | 2021 Management exercise all warrants within the framework of the 2018 incentive program Read more
May 11 | 2021 Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million. Read more
May 11 | 2021 Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK Read more
May 5 | 2021 Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021 Read more